Market Newsdesk

HERZLIYA, Israel and SAN JOSE, Calif., March 03, 2022 (GLOBE NEWSWIRE) — Otonomo Technologies Ltd. (Otonomo), the mobility intelligence company, today announced that it will participate in the following conferences in March:

• 34
  
  ^th
  
  Annual Roth Conference
  
  Format: In-person presentation and one-on-one meetings
  When: Tuesday, March 15 at 2:30 p.m. PST
  Presenter: Doron Simon, Executive Vice President, Corporate Development & Strategy

• Maxim Virtual Growth Conference
  
  Format: Virtual presentation, panel discussion and one-on-one meetings
  When: Panel discussion scheduled for Tuesday, March 29 at 11:00 a.m. EST
  Presenter: Ben Volkow, Chief Executive Officer

Live webcasts of the presentation and the panel can be accessed from Otonomo’s events page here. For more information regarding these events, please visit Otonomo’s investor relations page here.

Investors who wish to participate in a virtual or a live (where applicable) meeting with Otonomo’s management during the conferences may refer to their institutional sales contact.

About Otonomo 

Otonomo fuels a data ecosystem of OEMs, fleets, and more than 100 service providers spanning the transportation, mobility, and automotive industries. Our platform securely ingests more than 4 billion data points per day globally from over 50 million vehicles licensed on the platform and massive amounts of mobility demand data from multimodal sources, then reshapes and enriches it, to accelerate time to market for new services that improve the mobility and transportation experience. We provide deeper visibility and actionable insights to empower strategic data-driven decisions – taking the guesswork out of mobility and transportation planning, deployment, and operations. Privacy by design and neutrality are at the core of our platform, which enables GDPR, CCPA, and other privacy-regulation-compliant solutions using both personal and aggregate data. Use cases include emergency services, mapping, traffic management, EV management, subscription-based services, micro-mobility, parking, predictive maintenance, insurance, media, in-vehicle services, and dozens of smart city solutions.

More information is available at otonomo.io

Otonomo on Social Media

• Follow Otonomo on LinkedIn
• Like Otonomo on Facebook
• Follow Otonomo on Twitter

Investor Relations Contact:                                         
Miri Segal                                                                
MS-IR LLC                                                                

+1 (917)-607-8654                                                        
[email protected]                                                                 

SCOTTSDALE, Ariz., March 03, 2022 (GLOBE NEWSWIRE) — AMMO, Inc. (Nasdaq: POWW, POWWP) (“AMMO” or the “Company”), owner of GunBroker.com, the largest online marketplace serving the firearms and shooting sports industries, and a leading vertically integrated producer of high-performance ammunition and components, today issued a letter to shareholders from Fred Wagenhals, Chairman & CEO of AMMO Inc.

Dear Fellow AMMO, Inc. Shareholders,

On behalf of AMMO, Inc.’s (“AMMO”) Board of Directors, our senior management team and employees, we are delighted to have you as a shareholder and valued part of the AMMO family. I wanted to take a moment to send you this note to touch on some important “state of the union matters” that we are managing at AMMO.

As many of you know, we acquired GunBroker.com in 2021. Today, we find ourselves even more excited about our future together than we were the day we closed on the acquisition. We believed the two Companies shared common values across a wide range of topics, from our Nation’s ideals, a shared commitment to democracy and, in particular, our collective unwavering support for the Second Amendment.

The Company as now constituted presents the market with an impressive combination of AMMO’s technologically innovative manufacturing capabilities and processes with GunBroker.com’s online auction marketplace sporting a best-in-class secure transactional technology (the “Marketplace”). The combined enterprise has truly transformed AMMO into a unique opportunity where consumers and investors can find all their shooting needs under one roof, driven by a management team laser-focused on enhancing shareholder value through operational excellence and innovation. Your management team will continue to examine further growth opportunities through acquisition or otherwise in ways that are accretive to our family of companies, align with our shared values, and are best positioned to further enhance shareholder value in POWW and POWWP.

As a co-owner in AMMO, you are aware that GunBroker.com has been part of our burgeoning family for more than 10 months and has already significantly contributed to the Company’s growth – a trajectory we all work night and day to continue. We recently reported our quarterly financial results on Form 10-Q for the third quarter of our 2022 fiscal year and boasted record net revenues of $64.7 million, including $17.6 million from the Marketplace alone. We grew new users by an average of 55,000 per month and the auction numbers increased 33.45% from the prior year. The GunBroker.com team is now an integral part of the collective AMMO team, thriving in their new home as valued members of the AMMO family.

We’ve made a few other recent announcements I am certain you have read as they have come across the wire – a couple are worth repeating here. First, based upon your Company’s solid balance sheet and growing revenues, our Board of Directors recently provided management with an additional tool to increase shareholder value – the authorization to repurchase up to $30 million of AMMO shares. Second, we are proud to have announced that we offered to donate 1 million rounds of ammunition to the Ukrainian Armed Forces in support of their valiant defense against the unprovoked Russian aggression and threat to Ukraine’s independence. We are committed to living our values.

Within our ammunition and munition components operational unit, the industry remains strong, really constrained only by capacity. Management’s long-term strategic growth plans (which predated the outbreak of COVID and the resulting surge demand) will prove helpful in addressing some of that capacity deficit when we open our new state-of-the-art 160,000 square foot facility in Manitowoc, Wisconsin. Our plan is to continue our 24/7/365 focused efforts with the goal of tripling our ammunition capacity with the well-planned transition into our new plant, estimated to take place in the Summer of 2022. We also see a tremendous opportunity to continue to increase our market share through the GunBroker.com Marketplace and are regularly rolling out initiatives to accomplish that end.

We also recently announced that we are reiterating our guidance for the full 2022 fiscal year (period ending March 31, 2022) of approximately $250 million in revenue, an estimated 288% increase over the prior year period, which is projected to include anticipated Adjusted EBITDA of approximately $80 million.

Although we remain hyper-focused on today, this week and each quarter, we are always undertaking market analysis and looking ahead – and we see serial indications of continued growth for our business across all sectors and within each business unit. Many of you have heard me say that I am not a patient man, and that applies most directly in my drive to see the AMMO family succeed. The definition of “AMMO Family” to me is the individuals I am pleased to work with, and each of you shareholders that have seen fit to own a piece of this exciting organization.

Together we are building an unparalleled business that is serving large and growing markets, has unique and distinctive product offerings, each of which presents compelling competitive advantages. We would like to thank all our shareholders and supporters. We appreciate the confidence you have shown in us to date, and we look forward to earning your continued support.

Very Truly Yours,

Fred Wagenhals

Chairman & CEO

AMMO, Inc.

About AMMO, Inc.

With its corporate offices headquartered in Scottsdale, Arizona, AMMO designs and manufactures products for a variety of aptitudes, including law enforcement, military, sport shooting and self-defense. The Company was founded in 2016 with a vision to change, innovate and invigorate the complacent munitions industry. AMMO promotes branded munitions as well as its patented STREAK^™ Visual Ammunition, /stelTH/^™ subsonic munitions, and armor piercing rounds for military use. For more information, please visit: www.ammo-inc.com.

About GunBroker.com

GunBroker.com is the largest online marketplace dedicated to firearms, hunting, shooting and related products. Aside from merchandise bearing its logo, GunBroker.com currently sells none of the items listed on its website. Third-party sellers list items on the site and Federal and state laws govern the sale of firearms and other restricted items. Ownership policies and regulations are followed using licensed firearms dealers as transfer agents. Launched in 1999, GunBroker.com is an informative, secure and safe way to buy and sell firearms, ammunition, air guns, archery equipment, knives and swords, firearms accessories and hunting/shooting gear online. GunBroker.com promotes responsible ownership of guns and firearms. For more information, please visit: www.gunbroker.com.

Forward Looking Statements

This document contains certain “forward-looking statements”. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies, goals and objectives of management for future operations; any statements concerning proposed new products and services or developments thereof; any statements regarding future economic conditions or performance; any statements or belief; and any statements of assumptions underlying any of the foregoing.

Forward looking statements may include the words “may,” “could,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words, or the negative thereof. These forward-looking statements present our estimates and assumptions only as of the date of this report. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the dates on which they are made. We do not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the dates they are made. You should, however, consult further disclosures and risk factors we include in Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Reports filed on Form 8-K.

Investor Contact:

Reed Anderson
ICR
(646) 277-1260
[email protected]

GREENWICH, Conn., March 03, 2022 (GLOBE NEWSWIRE) — Oxford Square Capital Corp. (NasdaqGS: OXSQ) (NasdaqGS: OXSQL) (NasdaqGS: OXSQZ) (NasdaqGS: OXSQG) (the “Company,” “we,” “us” or “our”) announced today its financial results and related information for the quarter ended December 31, 2021.

• On March 1, 2022, our Board of Directors declared the following distributions on our common stock:

	Month Ending	Record Date	Payment Date	Amount Per Share
	April 30, 2022	April 15, 2022	April 29, 2022	$0.035
	May 31, 2022	May 17, 2022	May 31, 2022	$0.035
	June 30, 2022	June 16, 2022	June 30, 2022	$0.035

• Net asset value (“NAV”) per share as of December 31, 2021 stood at $4.92, compared with a NAV per share on September 30, 2021 of $5.03.

• Net investment income (“NII”), calculated in accordance with U.S. generally accepted accounting principles, was approximately $4.5 million, or $0.09 per share, for the quarter ended December 31, 2021, compared with approximately $4.0 million, or $0.08 per share, for the quarter ended September 30, 2021.
• Total investment income for the quarter ended December 31, 2021 amounted to approximately $10.2 million, compared with approximately $9.8 million for the quarter ended September 30, 2021.
  • For the quarter ended December 31, 2021 we recorded investment income from our portfolio as follows:
    • $4.8 million from our CLO equity, and
    • $5.3 million from our debt investments and other income
• Our total expenses for the quarter ended December 31, 2021 were approximately $5.7 million, compared with total expenses of approximately $5.8 million for the quarter ended September 30, 2021.
• As of December 31, 2021, the following metrics applied (note that none of these metrics represented a total return to shareholders):
  • The weighted average yield of our debt investments was 7.7% at current cost, compared with 7.5% as of September 30, 2021.
  • The weighted average effective yield of our CLO equity investments at current cost was 9.1%, which was approximately the same as of September 30, 2021.
  • The weighted average cash distribution yield of our cash income producing CLO equity investments at current cost was 21.2%, compared with 19.6% as of September 30, 2021.
• For the quarter ended December 31, 2021, we recorded a net increase in net assets resulting from operations, consisting of:
  • NII of approximately $4.5 million;
  • Net realized losses of approximately $3.7 million; and
  • Net unrealized depreciation of approximately $0.7 million. 

• During the fourth quarter of 2021, we made investments of approximately $23.3 million, received $1.6 million from repayments and amortization payments on our debt investments, and received $10.3 million from sales of investments.
• Our weighted average credit rating was 2.1 based on total fair value and 2.3 based on total principal amount as of December 31, 2021, compared with 2.0 and 2.3, respectively, as of September 30, 2021.
• As of December 31, 2021, we had three debt investments on non-accrual status, with a combined fair value of $1.3 million. Also, as of December 31, 2021, our preferred equity investments in one of our portfolio companies were on non-accrual status, which had an aggregate fair value of approximately $772,000.

We will hold a conference call to discuss fourth quarter results today, Thursday, March 3rd, 2022 at 9:00 AM ET. The toll-free dial-in number is 1-844-200-6205, access code number 094576. There will be a recording available for 30 days. If you are interested in hearing the recording, please dial 1-866-813-9403. The replay pass-code number is 501865.

A presentation containing further detail regarding our quarterly results of operations has been posted under the Investor Relations section of our website at www.oxfordsquarecapital.com.

OXFORD SQUARE CAPITAL CORP.

STATEMENTS OF ASSETS AND LIABILITIES

	December 31, 2021				December 31, 2020
ASSETS
Non-affiliated/non-control investments (cost: $495,212,632 and $407,547,351, respectively)	$	420,038,717			$	294,674,000
Affiliated investments (cost: $16,836,822 and $16,836,822, respectively)		772,491				—
Cash equivalents		9,015,700				59,137,284
Interest and distributions receivable		3,064,477				2,299,259
Securities sold not settled		—				950,000
Other assets		615,109				597,238
Total assets	$	433,506,494			$	357,657,781
LIABILITIES
Notes payable – 6.50% Unsecured Notes, net of deferred issuance costs of $730,361 and $1,055,065, respectively	$	63,639,864			$	63,315,160
Notes payable – 6.25% Unsecured Notes, net of deferred issuance costs of $1,009,924 and $1,243,082, respectively		43,780,826				43,547,668
Notes payable – 5.50% Unsecured Notes, net of deferred issuance costs of $2,539,305 and $0, respectively		77,960,695				—
Securities purchased not settled		—				23,156,556
Base Fee and Net Investment Income Incentive Fee payable to affiliate		1,688,712				1,159,703
Accrued interest payable		1,216,109				478,191
Accrued expenses		625,163				573,977
Total liabilities		188,911,369				132,231,255
COMMITMENTS AND CONTINGENCIES (Note 9)
NET ASSETS
Common stock, $0.01 par value, 100,000,000 shares authorized; 49,690,059 and 49,589,607 shares issued and outstanding, respectively		496,900				495,895
Capital in excess of par value		434,462,322				452,650,210
Total distributable earnings/(accumulated losses)		(190,364,097	)			(227,719,579	)
Total net assets		244,595,125				225,426,526
Total liabilities and net assets	$	433,506,494			$	357,657,781
Net asset value per common share	$	4.92			$	4.55

OXFORD SQUARE CAPITAL CORP.

STATEMENTS OF OPERATIONS

		Year Ended December 31, 2021				Year Ended December 31, 2020				Year Ended December 31, 2019
INVESTMENT INCOME
From non-affiliated/non-control investments:
Interest income – debt investments		$	17,440,229			$	20,252,055			$	28,000,283
Income from securitization vehicles and investments			18,691,631				15,014,000				25,244,866
Other income			1,043,153				676,450				1,694,434
Total investment income from non-affiliated/non-control investments			37,175,013				35,942,505				54,939,583
From affiliated investments:
Dividend income – non-cash			—				—				7,710,805
Interest income – debt investments			—				—				—
Total investment income from affiliated investments			—				—				7,710,805
Total investment income			37,175,013				35,942,505				62,650,388
EXPENSES
Interest expense			10,495,897				7,878,906				9,901,426
Base Fee			6,287,173				4,525,034				6,704,467
Professional fees			1,910,390				1,545,279				1,454,942
Compensation expense			723,931				708,350				832,256
Director’s fees			490,500				441,500				417,500
Insurance			422,805				330,746				281,146
Transfer agent and custodian fees			222,581				206,686				239,323
General and administrative			521,541				591,512				829,476
Total expenses before incentive fees			21,074,818				16,228,013				20,660,536
Net Investment Income Incentive Fees			—				—				3,511,493
Capital gains incentive fees			—				—				—
Total incentive fees			—				—				3,511,493
Total expenses			21,074,818				16,228,013				24,172,029
Net investment income			16,100,195				19,714,492				38,478,359
Net change in unrealized appreciation/(depreciation) on investments:
Non-Affiliate/non-control investments			37,699,436				(7,029,647	)			(50,107,582	)
Affiliated investments			772,491				(2,816,790	)			(19,386,212	)
Total net change in unrealized appreciation/(depreciation) on investments			38,471,927				(9,846,437	)			(69,493,794	)
Net realized losses:
Non-affiliated/non-control investments			(14,987,438	)			(8,151,553	)			(1,709,816	)
Extinguishment of debt			—				(5,211	)			(72,666	)
Total net realized losses			(14,987,438	)			(8,156,764	)			(1,782,482	)
Net increase/(decrease) in net assets resulting from operations	$		39,584,684		$		1,711,291		$		(32,797,917	)

	Year Ended December 31, 2021				Year Ended December 31, 2020				Year Ended December 31, 2019
Net increase in net assets resulting from net investment income per common share:
Basic and Diluted	$	0.32			$	0.40			$	0.81
Net increase/(decrease) in net assets resulting from operations per common share:
Basic and Diluted	$	0.80			$	0.03			$	(0.69	)
Weighted average shares of common stock outstanding:
Basic and Diluted		49,624,851				49,477,215				47,756,596

FINANCIAL HIGHLIGHTS

	Year Ended December 31, 2021				Year Ended December 31, 2020				Year Ended December 31, 2019				Year Ended December 31, 2018				Year Ended December 31, 2017
Per Share Data
Net asset value at beginning of year	$	4.55			$	5.12			$	6.60			$	7.55			$	7.50
Net investment income(1)		0.32				0.40				0.81				0.67				0.60
Net realized and unrealized gains (losses)(2)		0.47				(0.36	)			(1.49	)			(0.91	)			0.25
Net increase/(decrease) in net assets resulting from operations		0.79				0.04				(0.68	)			(0.24	)			0.85
Distributions per share from net investment income		(0.42	)			(0.61	)			(0.80	)			(0.73	)			(0.66	)
Distributions based on weighted average share impact		—				—				—				0.01				—
Tax return of capital distributions		—				—				—				(0.07	)			(0.14	)
Total distributions(3)		(0.42	)			(0.61	)			(0.80	)			(0.79	)			(0.80	)
Effect of shares issued/repurchased, gross		—				—				—				0.08				—
Net asset value at end of year	$	4.92			$	4.55			$	5.12			$	6.60			$	7.55
Per share market value at beginning of year	$	3.05			$	5.44			$	6.47			$	5.74			$	6.61
Per share market value at end of year	$	4.08			$	3.05			$	5.44			$	6.47			$	5.74
Total return based on Market Value(4)		47.38	%			(31.75	)%			(4.14	)%			26.95	%			(2.01	)%
Total return based on Net Asset Value(5)		17.36	%			0.82	%			(10.26	)%			(1.99	)%			11.33	%
Shares outstanding at end of year		49,690,059				49,589,607				48,448,987				47,650,959				51,479,409
Ratios/Supplemental Data (7)
Net assets at end of period (000’s)	$	244,595			$	225,427			$	247,999			$	314,724			$	388,419
Average net assets (000’s)	$	242,589			$	192,137			$	289,373			$	369,258			$	385,947
Ratio of expenses to average net assets		8.69	%			8.45	%			8.35	%			6.17	%			7.95	%
Ratio of net investment income to average net assets		6.64	%			10.26	%			13.30	%			9.07	%			7.96	%
Portfolio turnover rate(6)		11.09	%			23.72	%			12.75	%			35.18	%			43.02	%

(1)	Represents per share net investment income for the period, based upon weighted average shares outstanding.
(2)	Net realized and unrealized gains include rounding adjustments to reconcile change in net asset value per share.
(3)	Management monitors available taxable earnings, including net investment income and realized capital gains, to determine if a tax return of capital may occur for the year. To the extent the Company’s taxable earnings fall below the total amount of the Company’s distributions for that fiscal year, a portion of those distributions may be deemed a tax return of capital to the Company’s stockholders. The ultimate tax character of the Company’s earnings cannot be determined until tax returns are prepared after the end of the fiscal year.
(4)	Total return based on market value equals the increase or decrease of ending market value over beginning market value, plus distributions, assuming distribution reinvestment prices obtained under the Company’s distribution reinvestment plan, excluding any discounts divided by the beginning market value per share.
(5)	Total return based on net asset value equals the increase or decrease of ending net asset value over beginning net asset value, plus distributions, divided by the beginning net asset value.
(6)	Portfolio turnover rate is calculated using the lesser of the annual cash investment sales and repayments of principal or annual cash investment purchases over the average of the total investments at fair value.
(7)	The following table provides supplemental performance ratios measured for the years ended December 31, 2021, 2020, 2019, 2018 and 2017:

	Year Ended December 31, 2021			Year Ended December 31, 2020			Year Ended December 31, 2019			Year Ended December 31, 2018			Year Ended December 31, 2017
Ratio of expenses to average net assets:
Expenses before incentive fees	8.69	%		8.45	%		7.14	%		4.92	%		6.95	%
Net Investment Income Incentive Fees	—	%		—	%		1.21	%		1.24	%		1.00	%
Capital Gains Incentive Fees	—	%		—	%		—	%		—	%		—	%
Ratio of expenses, excluding interest expense, to average net assets	4.36	%		4.35	%		4.93	%		4.21	%		4.61	%

About Oxford Square Capital Corp.

Oxford Square Capital Corp. is a publicly-traded business development company principally investing in syndicated bank loans and debt and equity tranches of collateralized loan obligation (“CLO”) vehicles. CLO investments may also include warehouse facilities, which are financing structures intended to aggregate loans that may be used to form the basis of a CLO vehicle.

Forward-Looking Statements

This press release contains forward-looking statements subject to the inherent uncertainties in predicting future results and conditions. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements. These statements are not guarantees of future performance, conditions or results and involve a number of risks and uncertainties, including the impact of COVID-19 and related changes in base interest rates and significant market volatility on our business, our portfolio companies, our industry and the global economy. Certain factors could cause actual results and conditions to differ materially from those projected in these forward-looking statements. These factors are identified from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update such statements to reflect subsequent events, except as may be required by law.

Contact:
Bruce Rubin
203-983-5280

BOTHELL, Wash., March 03, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in two upcoming investment conferences as follows:

• Q1 Investor Summit
  Virtual
  Small & Micro Cap Conference being held March 8-9. Cocrystal senior management will present a company overview on March 9 at 11:45 a.m. Eastern time (8:45 a.m. Pacific time). A webcast of the presentation will be available live and archived here.

• 34
  
  ^th
  
  Annual Roth Conference being held March 13-15 at the Ritz-Carlton, Laguna Niguel in Dana Point, Calif.

“This is an exciting time at Cocrystal as we expect enrollment to begin shortly in our influenza A Phase 1 trial. We also plan to initiate first-in-human studies later this year with two different SARS-CoV-2 antivirals as potential oral and inhalation COVID-19 treatments,” said Sam Lee, Ph.D., Cocrystal’s President and interim co-CEO. “We are pleased to share our exciting plans with investors at these two conferences.”

“Given the growing global need for effective, safe antiviral treatments, we are rapidly advancing the development of compounds for multiple high-value indications,” said James Martin, CFO and interim co-CEO. “Our strong cash position and debt-free balance sheet position us to execute on our active clinical plans.”

About
Cocrystal
Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our expected enrollments to begin shortly in our influenza A Phase 1 trial, plans to initiate first-in-human studies later this year with two different SARS-CoV-2 antivirals as potential oral and inhalation COVID-19 treatments and the rapid advancement of the development of compounds for multiple high value indications. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks arising from supply chain disruptions on our ability to obtain products including raw materials and test animals as well as similar problems with our vendors and our current CRO and future CROs and CMOs, the impact of the COVID-19 pandemic including new variants on the national and global economy, the cooperation of the FDA in accelerating development in our COVID-19 program, our collaboration partners’ technology and software performing as expected, the results of future preclinical and clinical trials, general risks arising from clinical trials, receipt of regulatory approvals, regulatory changes, and development of effective treatments and/or vaccines by competitors, including as part of the programs financed by the U.S. government. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:

LHA Investor Relations
Jody Cain
310-691-7100
[email protected]

Media Contact:

JQA Partners
Jules Abraham
917-885-7378
[email protected]

# # #

BRANFORD, Conn., March 03, 2022 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) today announced the commencement of a registered public offering of unsecured, unsubordinated notes due five years from the date of issuance (“Notes”). The Notes will rank pari passu with all the company’s unsecured, unsubordinated indebtedness, whether currently outstanding or issued in the future. The Notes are expected to be listed on the NYSE American under the trading symbol “SCCE” and to trade thereon within 30 days of the original issue date. The interest rate and other terms of the Notes will be determined at the time of the pricing of the offering. The Notes have a private credit rating of BBB+ from Egan-Jones Ratings Company, an independent, unaffiliated rating agency. Egan-Jones is a Nationally Recognized Statistical Ratings Organization (NRSRO) and is recognized by the National Association of Insurance Commissioners (NAIC) as a Credit Rating Provider (CRP). Egan-Jones is also certified by the European Securities and Markets Authority (ESMA). A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.

Ladenburg Thalmann & Co. Inc., Janney Montgomery Scott LLC, InspereX LLC and William Blair & Company, LLC are acting as joint book-running managers for the offering. Colliers Securities LLC is acting as co-manager for the offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities in this offering or any other securities nor will there be any sale of the Notes or any other securities referred to in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

A registration statement relating to, among other things, the Notes, was filed and has been declared effective by the Securities and Exchange Commission. The offering is being made only by means of a related prospectus supplement and an accompanying base prospectus forming part of the effective registration statement, copies of which may be obtained, when available, from: Ladenburg Thalmann & Co. Inc. by written request addressed to Syndicate Department, 640 5th Avenue, 4th Floor, New York, NY 10019 (telephone number 1-800-573-2541) or by emailing [email protected]; Janney Montgomery Scott LLC, by written request to 1717 Arch Street Philadelphia, PA 19103 (telephone number 1-800-526-6397) or by emailing [email protected]; or InspereX LLC, Attn: Syndicate Department, 200 S. Wacker Drive, Suite 3400, Chicago, IL 60606 (telephone number 1-800-327-1546) or by emailing [email protected]; or William Blair & Company, LLC by written request to 150 North Riverside Plaza, Chicago, Illinois 60606 (telephone number 1-800-621-0687) or by emailing [email protected]. Copies may also be obtained for free by visiting EDGAR on the SEC’s website at http://www.sec.gov.

Sachem Capital Corp. has filed a preliminary prospectus supplement, dated March 3, 2022, with the Securities and Exchange Commission, which contains more detailed description of the Notes and the terms of the offering. The preliminary prospectus supplement, dated March 3, 2022, and the accompanying base prospectus, dated February 25, 2022, which contains other important information about Sachem Capital Corp., should be read carefully before investing in the Notes. Investors are advised to carefully consider their personal investment objectives, the risks relating to Sachem Capital Corp., in general, and to the Notes in particular, and other matters relating to Sachem Capital Corp., its business, operations and financial condition, before investing in the Notes.

About Sachem Capital Corp.

Sachem Capital Corp. specializes in originating, underwriting, funding, servicing, and managing a portfolio of first mortgage loans. It offers short-term (i.e., three years or less) secured, non­banking loans (sometimes referred to as “hard money” loans) to real estate investors to fund their acquisition, renovation, development, rehabilitation or improvement of properties located primarily in Connecticut. The company does not lend to owner occupants. The company’s primary underwriting criteria is a conservative loan to value ratio. The properties securing the company’s loans are generally classified as residential or commercial real estate and, typically, are held for resale or investment. Each loan is secured by a first mortgage lien on real estate. Each loan is also personally guaranteed by the principal(s) of the borrower, which guaranty may be collaterally secured by a pledge of the guarantor’s interest in the borrower. The company also makes opportunistic real estate purchases apart from its lending activities. The company believes that it qualifies as a real estate investment trust (REIT) for federal income tax purposes and has elected to be taxed as a REIT beginning with its 2017 tax year.

Forward Looking Statements

This press release may contain forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations for future operations, are forward-looking statements. The words “anticipate,” “estimate,” “expect,” “project,” “plan,” “seek,” “intend,” “believe,” “may,” “might,” “will,” “should,” “could,” “likely,” “continue,” “design,” and the negative of such terms and other words and terms of similar expressions are intended to identify forward- looking statements.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to several risks, uncertainties and assumptions as described in our Annual Report on Form 10-K for 2020 filed with the U.S. Securities and Exchange Commission on March 31, 2021. Because of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. In addition, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. We disclaim any duty to update any of these forward-looking statements.

All forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary statements as well as others made in this press release. You should evaluate all forward-looking statements made by us in the context of these risks and uncertainties.

Investor & Media Contact:

Crescendo Communications, LLC
Email: [email protected]
Tel: (212) 671-1021

LAS VEGAS, March 03, 2022 (GLOBE NEWSWIRE) — Full House Resorts (NASDAQ: FLL) announced that it will report its fourth quarter 2021 and full-year financial results on Tuesday, March 8, 2022, followed by a conference call at 4:30 p.m. ET (1:30 p.m. PT). Investors can access the live audio webcast from the Company’s website at www.fullhouseresorts.com under the investor relations section. The conference call can also be accessed by dialing (888) 254-3590 or, for international callers, (323) 794-2551.

A replay of the conference call will be available shortly after the conclusion of the call through March 22, 2022. To access the replay, please visit www.fullhouseresorts.com. Investors can also access the replay by dialing (844) 512-2921 or, for international callers, (412) 317-6671 and using the passcode 2361210.

Forward-looking Statements

This press release may contain statements by Full House Resorts, Inc. that are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Additional information concerning potential factors that could affect our financial condition and results of operations is included in the reports we file with the SEC, including, but not limited to, our Form 10-K for the most recently ended fiscal year and our other periodic reports filed with the SEC. We are under no obligation to (and expressly disclaim any such obligation to) update or revise our forward-looking statements as a result of new information, future events or otherwise, except as otherwise required by law. Actual results may differ materially from those indicated in the forward-looking statements.

About Full House Resorts, Inc.

Full House Resorts owns, leases, develops and operates gaming facilities throughout the country. The Company’s properties include Silver Slipper Casino and Hotel in Hancock County, Mississippi; Bronco Billy’s Casino and Hotel in Cripple Creek, Colorado; Rising Star Casino Resort in Rising Sun, Indiana; Stockman’s Casino in Fallon, Nevada; and Grand Lodge Casino, located within the Hyatt Regency Lake Tahoe Resort, Spa and Casino in Incline Village, Nevada. The Company is currently constructing Chamonix Casino Hotel, a new luxury hotel and casino in Cripple Creek, Colorado. In December 2021, the Company was chosen by the Illinois Gaming Board to develop American Place, a new gaming and entertainment destination to be built in Waukegan, Illinois, subject to final regulatory approvals. For further information, please visit www.fullhouseresorts.com.

Contact:
Lewis Fanger, Chief Financial Officer
Full House Resorts, Inc.
(702) 221-7800
www.fullhouseresorts.com

HORSHAM, Pa., March 03, 2022 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the Company will participate in the upcoming Oppenheimer 32^nd Annual Healthcare Conference.

STRATA Skin Sciences’ management is scheduled to present on Tuesday, March 15^th at 2:00 pm Eastern Time. Management will also participate in 1×1 meetings throughout out the day. Interested parties may access a live and archived webcast of the presentation on the investor section of the Company’s website at www.strataskinsciences.com.

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the in-office treatment of dermatologic conditions. Its products include the XTRAC®, XTRAC Momentum™ 1.0 and Pharos® excimer lasers, VTRAC® lamp systems, and TheraClear treatment system utilized in the treatment of psoriasis, vitiligo, acne and various other skin conditions.

The Company’s proprietary XTRAC, XTRAC Momentum™ 1.0 and recently acquired Pharos excimer lasers deliver a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone. The technology is covered by multiple patents. Additionally, STRATA’s recently acquired assets related to Theravant Corporation’s TheraClear system allows the company the expand into the estimated $5.5 billion U.S. acne care market.

STRATA’s unique business model in the U.S. leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.

Investor Contact

Jack Droogan
(203) 585-4140
[email protected]

FREMONT, Calif., March 03, 2022 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, announced today that Enphase installers in Oregon have seen growing deployments of the Enphase^® Energy System, powered by IQ™ Microinverters and IQ™ Batteries, after last summer’s heatwave left many without power and fueled consumer interest in solar plus battery storage home energy solutions.

Oregon is steadily growing its residential battery capacity year over year. Forecasts estimate deployments will grow five-fold by 2026, according to the most recent U.S. Energy Storage Monitor report from the Energy Storage Association and Wood Mackenzie.

“Since 2005, E2 Solar has been committed to installing only the best products available,” said Kelli Kewitt, president of E2 Solar, an Enphase Gold level installer. “We believe the Enphase IQ Battery is one of the highest quality and highest performing home battery solutions on the market. It provides homeowners with energy choices, allowing them to achieve various levels of backup or outright energy independence. We have so much faith in the IQ system, that it is the only energy storage product we offer our customers.”

Oregon homeowners can now choose to install Enphase’s revolutionary IQ8™ Microinverters. IQ8 can provide Sunlight Backup during an outage, even without a battery. For homeowners who want a battery, there are no sizing restrictions on pairing an Enphase IQ Battery with IQ8 Microinverters.

“Our customers trust the Enphase IQ Battery to provide safe and reliable backup power during outages,” said Kelli Wolford, general manager at Elemental Energy, an Enphase Gold level installer. “We’re also thrilled to further extend access to energy resilience with Enphase’s IQ8 solar microinverter, which gives our customers an industry-leading backup solution that meets their specific needs.”

“Our team of experienced installers are dedicated to delivering the future of clean energy to Oregon homeowners today,” said Jordan Weisman, owner of Sunbridge Solar, an Enphase Silver level installer. “We are proud to partner with Enphase and deploy its best-in-class battery and microinverter technologies so that homeowners can start generating, storing, and controlling their own clean energy.”

​​Enphase delivers a safe solar-plus-battery solution which does not expose installers or homeowners to high-voltage DC. Enphase IQ Batteries feature Lithium Iron Phosphate (LFP) battery chemistry, which provides a long cycle life and safer operation through excellent thermal stability. The batteries are equipped with Enphase Power Start™ technology, which helps seamlessly power-up air conditioners and well-pumps. The Enphase IQ Batteries accommodate over-the-air software upgrades and come with a 10-year limited warranty, while Enphase IQ8 solar microinverters come with a 25-year limited warranty.

“Extreme weather events across the U.S. have disrupted electric grids on numerous occasions, causing homeowner interest in solar and battery systems to rise at never before seen levels,” said Dave Ranhoff, chief commercial officer at Enphase Energy. “This trend has certainly been true in Oregon, and we’re grateful to the installers in our network who are committed to delivering our industry-leading solar and battery solutions. With the Enphase Energy System, customers can reap the benefits of clean energy and feel secure in their homes.”

For more information about Enphase IQ Batteries and IQ8 Microinverters, please visit the Enphase website.

About Enphase Energy, Inc.

Enphase Energy, a global energy technology company based in Fremont, CA, is the world’s leading supplier of microinverter-based solar and battery systems that enable people to harness the sun to make, use, save, and sell their own power—and control it all with a smart mobile app. The company revolutionized the solar industry with its microinverter-based technology and builds all-in-one solar, battery, and software solutions. Enphase has shipped more than 42 million microinverters, and approximately 1.9 million Enphase-based systems have been deployed in more than 130 countries. For more information, visit https://www.enphase.com and follow the company on Facebook, LinkedIn and Twitter.

© 2022 Enphase Energy, Inc. All rights reserved. Enphase, the “e” logo, IQ, IQ8, Power Start, and certain other names and marks are registered trademarks of Enphase Energy, Inc. Other names are for informational purposes and may be trademarks of their respective owners.

Forward-Looking Statements

This press release may contain forward-looking statements, including statements related to the expected capabilities and performance of Enphase Energy’s technology and products, including safety, quality and reliability; the availability and market adoption of our products; market growth; market demand; increased deployments; and the performance by our installation partners. These forward-looking statements are based on Enphase’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of certain risks and uncertainties, including those risks described in more detail in Enphase’s most recent Annual Report on Form 10-K and other documents on file with the SEC and available on the SEC’s website at www.sec.gov. Enphase Energy undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, or changes in its expectations, except as required by law.

Contact:

Enphase Energy
[email protected]

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at two upcoming investor conferences in March.

Details of the events are as follows:

Conference: 34^th Annual ROTH Conference
Date: March 13 – 15, 2022
Time: Pre-recorded Corporate Presentation available on demand

Conference: Oppenheimer 32^nd Annual Healthcare Conference
Date: Wednesday, March 16, 2022
Time: Live virtual Corporate Presentation at 4:40pm EDT / 1:40pm PDT

In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. Following the events, a replay of each presentation will be available on the Investor’s section of the company’s website at www.atyrpharma.com.

Abo
ut aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

Contact:

Ashlee Dunston
Director, Investor Relations and Corporate Communications
[email protected]

Base Interest Rate of 8% for Capital Projects and 10% for Working Capital Line

CUPERTINO, CA, March 03, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Aemetis, Inc. (NASDAQ: AMTX), a renewable fuels company focused on negative carbon intensity products, announced today the closing of two new, lower interest rate credit facilities with aggregate availability of up to $100 million, comprised of up to $50 million for projects that produce lower carbon intensity renewable products and up to $50 million for working capital. In connection with the closing of the new credit facilities, Aemetis repaid $16 million of higher interest rate debt, building upon the more than $60 million of higher interest rate debt repaid during 2021. 

The base interest rates under the new credit facilities are 8% for capital projects and 10% for working capital financing and were provided by Third Eye Capital of Toronto, Canada, which has funded Aemetis as a senior lender since 2008.  The credit facilities are expected to provide funding for the Aemetis projects that reduce the carbon intensity of renewable fuels, including a zero carbon intensity solar array and extensive process equipment electrification upgrades to the Keyes ethanol plant, a sustainable aviation fuel (SAF) and renewable diesel plant, and carbon sequestration facilities.

“This new, lower-cost financing builds on our relationship with Third Eye Capital that began with our first funding in 2008,” said Eric McAfee, Chairman and CEO of Aemetis.  “We sincerely appreciate their support for carbon reduction investments and other growth projects at Aemetis.  This lower interest rate debt funding is designed to fund the development of the 90 million gallon per year Carbon Zero 1 sustainable aviation fuel and renewable diesel plant; fully fund the remaining Keyes plant upgrades to install solar and mechanical vapor recompression; and fully fund the two characterization wells, engineering and permitting for the Aemetis Carbon Capture subsidiary to submit EPA Class VI CO2 sequestration licenses at our two biofuels plant sites.” 

Both credit facilities have availability provisions based on the qualified use of funds and other factors.  Consideration to the lender includes a warrant to purchase 500,000 shares of Aemetis common stock at a $20 per share exercise price and a warrant to purchase 100,000 shares of Aemetis common stock at an exercise price equal to the 30 day VWAP of Aemetis common stock ($10.20).

The new debt facilities are expected to provide the remaining funding required for engineering and permitting of the Carbon Zero renewable jet and diesel plant in Riverbank, California from Aemetis prior to completion of project debt financing.  Aemetis has invested more than $32 million of cash and grants in the renewable jet and diesel plant.

In addition to a $3.2 billion, 10-year renewable diesel supply agreement with a leading travel stop company, Aemetis has signed $2.5 billion of sustainable aviation fuel supply agreements with Delta Air Lines, American Airlines and Japan Airlines to supply a 40% blend of SAF and 60% petroleum jet fuel to San Francisco Airport.  An additional $1 billion of Memorandum of Understandings have been signed with other members of the oneworld Alliance, which are expected to be converted to signed agreements by the end of Q2 2022.

About Aemetis

Aemetis has a mission to transform renewable energy with below zero carbon intensity transportation fuels. Aemetis has launched the Carbon Zero production process to decarbonize the transportation sector using today’s infrastructure. 

Aemetis Carbon Zero products include zero carbon fuels that can “drop in” to be used in airplane, truck, and ship fleets. Aemetis low-carbon fuels have substantially reduced carbon intensity compared to standard petroleum fossil-based fuels across their lifecycle. 

Headquartered in Cupertino, California, Aemetis is a renewable natural gas, renewable fuel and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace petroleum-based products and reduce greenhouse gas emissions. Founded in 2006, Aemetis has completed Phase 1 and is expanding a California biogas digester network and pipeline system to convert dairy waste gas into Renewable Natural Gas. Aemetis owns and operates a 65 million gallon per year ethanol production facility in California’s Central Valley near Modesto that supplies about 80 dairies with animal feed. Aemetis also owns and operates a 50 million gallon per year production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India and Europe.  Aemetis is developing the Carbon Zero sustainable aviation fuel (SAF) and renewable diesel fuel biorefineries in California to utilize distillers corn oil and other renewable oils to produce low carbon intensity renewable jet and diesel fuel using cellulosic hydrogen from waste orchard and forest wood, while pre-extracting cellulosic sugars from the waste wood to be processed into high value cellulosic ethanol at the Keyes plant. Aemetis holds a portfolio of patents and exclusive technology licenses to produce renewable fuels and biochemicals. For additional information about Aemetis, please visit www.aemetis.com.

Safe Harbor Statement 

This news release contains forward-looking statements, including statements regarding assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this news release include, without limitation, statements relating to the development and construction of the Keyes plant upgrades, sustainable aviation fuel and renewable diesel plant and carbon sequestration facilities, our compliance with governmental programs, the use of proceeds with respect to the new credit facilities, the total availability under our credit facilities, the conversion of memorandum of understandings with respect to SAF to signed agreements, and our ability to access markets and funding to execute our business plan.  Words or phrases such as “anticipates,” “may,” “will,” “should,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “showing signs,” “targets,” “view,” “will likely result,” “will continue” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties.  Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, competition in the ethanol, biodiesel and other industries in which we operate, commodity market risks including those that may result from current weather conditions, financial market risks, customer adoption, counter-party risks, risks associated with changes to federal policy or regulation, and other risks detailed in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2020 and in our subsequent filings with the SEC.  We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.

External Investor Relations

Contact:

Kirin Smith

PCG Advisory Group

(646) 863-6519

[email protected]

Company Investor Relations/

Media Contact:

Todd Waltz

(408) 213-0940

[email protected]